bioAffinity Technologies, Inc. (BIAF): Nasdaq/NYSE listing notice — bioAffinity receives Nasdaq delisting notice for bid price below $1.00

bioAffinity Technologies, Inc.

Received Nasdaq notice on Feb 7, 2025; common stock bid price below $1.00 for 30 consecutive business days.
Has 180-day compliance period until Aug 6, 2025 to regain minimum $1.00 closing bid price.
No immediate effect on listing or trading; stock continues on Nasdaq Capital Market under BIAF.
Company to consider available options to regain compliance; may be eligible for additional time if not compliant by August.
Potential failure to cure could result in delisting if not resolved.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

bioAffinity Technologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (December 23, 2024 through February 6, 2025), the Company’s common stock did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per share as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

bioAffinity Technologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3

View on SEC.gov

Browse all listing & compliance notices →

bioAffinity Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-005450

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.